Predictive Value of ¹⁸F-FDG PET/CT in LA-HNSCC Patients Undergoing Neoadjuvant Chemoimmunotherapy: A Prospective Study.

IF 2.9 3区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral diseases Pub Date : 2025-02-17 DOI:10.1111/odi.15276

Rong Huang, Xiaoxu Lu, Xueming Sun, Hui Wu

{"title":"Predictive Value of 18F-FDG PET/CT in LA-HNSCC Patients Undergoing Neoadjuvant Chemoimmunotherapy: A Prospective Study.","authors":"Rong Huang, Xiaoxu Lu, Xueming Sun, Hui Wu","doi":"10.1111/odi.15276","DOIUrl":null,"url":null,"abstract":"Objective: The study evaluates the efficacy of 18F-2-fluoro-2-deoxy-d-glucose FDG PET/CT in predicting outcomes in patients with advanced head and neck squamous cell carcinoma receiving neoadjuvant chemoimmunotherapy.Methods: In this prospective study, we compared the parameters of 63 patients with LA-HNSCC who underwent 18F-FDG PET/CT before neoadjuvant chemoimmunotherapy, divided into responders (47) and non-responders (16), after three cycles of neoadjuvant chemoimmunotherapy. The ratio of the maximum standardized uptake value (SUVmax) of the primary tumor to the SUVmean of the normal tissue (muscle and blood) was recorded as the target background ratio (TBR muscle and TBR blood).Results: The SUVmean and TBRblood of the primary tumor were significantly lower in the responding group than in the non-responding group. Receiver operating characteristic (ROC) curve analysis identified SUVmean (area under the curve (AUC) = 0.931, p = 0.001) and TBRblood (AUC = 0.894, p = 0.001) as significant predictors of neoadjuvant chemoimmunotherapy efficacy. The study found that SUVmean, TBRblood, age, and Eastern Cooperative Oncology Group (ECOG) scores significantly correlated with short-term efficacy, while SUVmean was an independent predictor.Conclusion: In 18F-FDG PET/CT scans, higher baseline SUVmean and TBRblood were associated with a poor short-term response to neoadjuvant chemoradiotherapy in patients with LA-HNSCC.","PeriodicalId":19615,"journal":{"name":"Oral diseases","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/odi.15276","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The study evaluates the efficacy of ¹⁸F-2-fluoro-2-deoxy-d-glucose FDG PET/CT in predicting outcomes in patients with advanced head and neck squamous cell carcinoma receiving neoadjuvant chemoimmunotherapy.

Methods: In this prospective study, we compared the parameters of 63 patients with LA-HNSCC who underwent ¹⁸F-FDG PET/CT before neoadjuvant chemoimmunotherapy, divided into responders (47) and non-responders (16), after three cycles of neoadjuvant chemoimmunotherapy. The ratio of the maximum standardized uptake value (SUVmax) of the primary tumor to the SUVmean of the normal tissue (muscle and blood) was recorded as the target background ratio (TBR muscle and TBR blood).

Results: The SUVmean and TBRblood of the primary tumor were significantly lower in the responding group than in the non-responding group. Receiver operating characteristic (ROC) curve analysis identified SUVmean (area under the curve (AUC) = 0.931, p = 0.001) and TBRblood (AUC = 0.894, p = 0.001) as significant predictors of neoadjuvant chemoimmunotherapy efficacy. The study found that SUVmean, TBRblood, age, and Eastern Cooperative Oncology Group (ECOG) scores significantly correlated with short-term efficacy, while SUVmean was an independent predictor.

Conclusion: In ¹⁸F-FDG PET/CT scans, higher baseline SUVmean and TBRblood were associated with a poor short-term response to neoadjuvant chemoradiotherapy in patients with LA-HNSCC.

查看原文本刊更多论文

18F-FDG PET/CT在接受新辅助化疗免疫治疗的LA-HNSCC患者中的预测价值：一项前瞻性研究

目的：评价18f -2-氟-2-脱氧-d-葡萄糖FDG PET/CT对晚期头颈部鳞状细胞癌患者新辅助化疗免疫治疗预后的预测作用。方法：在这项前瞻性研究中，我们比较了63例LA-HNSCC患者在新辅助化学免疫治疗前接受18F-FDG PET/CT的参数，分为反应（47）和无反应（16），经过三个周期的新辅助化学免疫治疗。将原发肿瘤的最大标准化摄取值（SUVmax）与正常组织（肌肉和血液）的suv平均值之比作为目标背景比（TBR肌肉和TBR血液）。结果：反应组原发肿瘤的SUVmean和TBRblood明显低于无反应组。受试者工作特征（ROC）曲线分析发现，SUVmean（曲线下面积(AUC) = 0.931, p = 0.001）和TBRblood （AUC = 0.894, p = 0.001）是新辅助化疗免疫治疗疗效的显著预测因子。研究发现，SUVmean、TBRblood、年龄和东部肿瘤合作组（ECOG）评分与短期疗效显著相关，而SUVmean是一个独立的预测因子。结论：在18F-FDG PET/CT扫描中，较高的基线SUVmean和TBRblood与LA-HNSCC患者对新辅助放化疗的短期不良反应相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oral diseases 医学-牙科与口腔外科

CiteScore

7.60

自引率

5.30%

发文量

325

审稿时长

4-8 weeks

期刊介绍： Oral Diseases is a multidisciplinary and international journal with a focus on head and neck disorders, edited by leaders in the field, Professor Giovanni Lodi (Editor-in-Chief, Milan, Italy), Professor Stefano Petti (Deputy Editor, Rome, Italy) and Associate Professor Gulshan Sunavala-Dossabhoy (Deputy Editor, Shreveport, LA, USA). The journal is pre-eminent in oral medicine. Oral Diseases specifically strives to link often-isolated areas of dentistry and medicine through broad-based scholarship that includes well-designed and controlled clinical research, analytical epidemiology, and the translation of basic science in pre-clinical studies. The journal typically publishes articles relevant to many related medical specialties including especially dermatology, gastroenterology, hematology, immunology, infectious diseases, neuropsychiatry, oncology and otolaryngology. The essential requirement is that all submitted research is hypothesis-driven, with significant positive and negative results both welcomed. Equal publication emphasis is placed on etiology, pathogenesis, diagnosis, prevention and treatment.